CALGARY, AB / ACCESSWIRE / January 29, 2016 / Seair Inc. (TSXV: SDS) (“Seair” or the “Corporation”) announced that it has filed its financial statements and Management’s Discussion and Analysis for the quarter ended November 30, 2015. Interested parties may view or download copies of these documents from www.SEDAR.com.

About Seair Inc.

The Company is a water technology corporation active at the heart of water-energy nexus that provides proprietary diffusion technology with global applications in several industry sectors, including oil & gas, mining, municipal and industrial wastewater applications. The key proprietary technology of the company solves critical oil-water separation (de-oiling) cost-effectively for oil producers. Seair has commercialized proprietary technology that can diffuse gases, such as oxygen, ozone and carbon dioxide, into liquids more effectively and with lower power consumption than the competition. Seair’s patented technologies can produce micron size bubbles that are more efficient than other diffusion technologies because the diffused gases remain in solution for extended periods of time, leading to increased productivity and lower operating costs. Seair has been working with customers in the Oil and Gas industry for over five years. Seair applications include oil sands SAGD water solutions, frac and produced water treatment, industrial ponds treatment, mine dewatering/treatment, end-to-end sewage treatment for permanent residential communities and remote work camps, golf course irrigation and pond treatment and most recently, industrial emissions treatment. Parties interested in obtaining further information or receiving news releases and corporate documents from Seair may email such requests to info@seairinc.com or visit the Seair website at www.seairinc.com.

Statement Regarding Forward-Looking Information

This news release of Seair contains statements that constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Seair’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur. Forward-looking statements in this document include statements regarding Seair’s expectations regarding the regulatory approval of the issuance of Common Shares in satisfaction of interest payable on the Debentures and the timing of the delivery of such Common Shares. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements, and readers are cautioned not to place undue reliance on these forward-looking statements. Any factor could cause actual results to differ materially from Seair’s expectations. Seair undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Seair Inc.
Jim Laird, CFO
info@seairinc.com

SOURCE: Seair Inc.

ReleaseID: 436186

TORONTO, ON / ACCESSWIRE / January 29, 2016 / DNI Metals Inc. (CSE: DNI) (“DNI” or the “Company”) announces that, further to its news release dated January 29, 2016, the Company has closed, subject to final Regulatory approval, the first tranche (the “First Tranche”) of its non-brokered private placement financing (the “Private Placement”). The First Tranche comprises 2,000,000 units of the Company (the “Units”) at a price of CDN$0.05 per Unit for aggregate gross proceeds of CDN$100,000. Each Unit consists of one common share of the Company (a “Common Share”) and one common share purchase warrant of the Company (“Warrant”). Each Warrant will entitle the holder to acquire one additional Common Share at a price of CDN$0.10 per Common Share for a period of 18 months following the date of the closing of the First Tranche. All securities issued under the First Tranche are subject to a four month hold period expiring on May 29th 2016. Pursuant to this placement, DNI’s officers and directors subscribed for 70.5% of the securities in the first tranche of the Private Placement.

An aggregate cash commission of $8,000, plus an aggregate of 160,000 non-transferable common share purchase warrants (the “Finder’s Warrants”) is, subject to final Regulatory approval, payable in connection with the closing of the First Tranche. Each Finder’s Warrant will be exercisable into one Common Share at an exercise price of CDN$.10 for a period of 18 months following issuance.

The Company expects to use the proceeds raised from the First Tranche to fund general and operating working capital.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

DNI – Canadian Securities Exchange
DG7N – Frankfurt
Issued: 29,586,204

For further information, contact:

DNI Metals Inc. – Dan Weir, President & CEO 416-595-1195

DanWeir@dnimetals.com
email ir@dnimetals.com. Also visit www.dnimetals.com

Katrin Tosine
Capital Markets and Investor Relations Advisor
kat@dnimetals.com
647.388.4984

We seek Safe Harbour. This announcement includes forward looking statements. While these statements represent DNI’s best current judgment, they are subject to risks and uncertainties that could cause actual results to vary, including risk factors listed in DNI’s Annual Information Form and its MD&As, all of which are available from SEDAR and on its website.

Caution Regarding Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the anticipated benefits of the Transaction to the Company and shareholders of the Company; the pro forma shareholdings of the Company’s shareholders in DNI; execution of the Definitive Agreement, the timing and receipt of the required shareholder, stock exchange and regulatory approvals for the Transaction; the anticipated timing for mailing the management information circular to the shareholders of the Company in respect of the Transaction; the closing of the Transaction; the length of the current market cycle and requirements for an issuer to survive in the current market cycle; future growth potential of DNI and its business; and future mine development plans.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: satisfaction or waiver of all applicable conditions to closing of the Transaction (including receipt of all necessary shareholder, stock exchange and regulatory approvals or consents, and the absence of material changes with respect to the parties and their respective businesses); the synergies expected from the Transaction not being realized; business integration risks; fluctuations in general macroeconomic conditions; fluctuations in securities markets and the market price of the DNI Shares and the Company Shares; fluctuations in spot and forward prices of graphite or certain other commodities; fluctuations in currency markets (such as the Canadian dollar to United States dollar exchange rate); change in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formations pressures, cave-ins and flooding); inability to obtain adequate insurance to cover risks and hazards; the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities and indigenous populations; availability of increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); and title to properties. In addition, the failure of a party to comply with the terms of the Definitive Agreement (assuming the Definitive Agreement is entered into) may result in that party being required to pay a non–completion or other fee to the other party, the result of which could have a material adverse effect on the paying party’s financial position and results of operations and its ability to fund growth prospects and current operations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended.

Readers should not place undue reliance on the forward–looking statements and information contained in this news release. Except as required by law, the Company assumes no obligation to update the forward–looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

SOURCE: DNI Metals Inc.

ReleaseID: 436187

TORONTO, ON and NEW YORK, NY / ACCESSWIRE / January 29, 2016 / Micromem Technologies Inc. (CSE: MRM) (OTCQX: MMTIF) (the “Company”) has re-engaged RB Milestone Group LLC (“RB Milestone”) to continue their services and update its current institutional research report on the Company. To pay for the services of RB Milestone the Company has completed a private placement totalling 183,334 common shares at a subscription price of US $0.30 (CAD $0.42) per share for gross proceeds of USD $55,000 (CAD $77,402.). The common shares are subject to resale restrictions.

About Micromem and MASTInc

MASTInc is a wholly owned U.S.-based subsidiary of Micromem Technologies Inc., a publicly traded (OTCQX: MMTIF) (CSE: MRM) company. MASTInc analyzes specific industry sectors to create intelligent game-changing applications that address unmet market needs. By leveraging its expertise and experience with sophisticated magnetic sensor applications, MASTInc successfully powers the development and implementation of innovative solutions for oil & gas, utilities, automotive, healthcare, government, information technology, manufacturing, and other industries. Visit www.micromeminc.com www.mastinc.com.

Safe Harbor Statement

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company’s actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; continued consumer adoption of digital technology; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer and technological demands; inability to replace significant customers; seasonal nature of our business; and other risks detailed in our filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential,” and similar expressions may be used to identify forward-looking statements.

The CSE or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release that has been prepared by management.

Listing: NASD OTCQX – Symbol: MMTIF

CSE – Symbol: MRM
Shares issued: 197,176,368
SEC File No: 0-26005

Investor Contact:

info@micromeminc.com
Tel. 416-364-2023

Subscribe to receive News Releases by Email on our website’s home page. www.micromeminc.com

SOURCE: Micromem Technologies Inc.

ReleaseID: 436189

DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2016 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced total net revenues of $23.4 million for the year ended October 31, 2015, a decrease of approximately $4.2 million, or 15.1%, when compared to last year. The revenue decrease is mainly attributable to a decline from projects in the United States and Europe consulting markets.

Net income for year ended October 31, 2015 was approximately $1.6 million, a decrease of $0.8 million when compared to last year. The decrease was mainly attributable to the decline in revenue, partially offset by a reduction of business development and operational support expenses, and the impact of the effective income tax rates (including Puerto Rico favorable tax grant) over income before tax.

“We are continuing our strategic alignment and investment of working capital in resources and infrastructure to drive consulting business development in existing and new markets, expansion of our Puerto Rico Lab facilities, development of a new Lab facility in Spain and enhancing our Calibrations division facility in Puerto Rico,” said Victor Sanchez, CEO of Pharma-Bio Serv. “We are confident that our investment in our consulting team, new markets and services, Lab facilities and equipment during fiscal year 2016 will provide sustainable growth to the Company in future years,” he added.

About Pharma-Bio Serv, Inc.

Pharma-Bio Serv is a compliance, project management and technology transfer support consulting firm, headquartered in Puerto Rico, with operations in the U.S., Ireland, Spain and Brazil. Pharma-Bio Serv’s core business is FDA and other international regulatory compliance agency related services, with integrated portfolio services including microbiological and chemical testing services for clients in the Pharmaceutical, Biotechnology, Chemical, Medical Device, Cosmetic, Food and Allied Products industries. The Company’s services also include information technology consulting through our “Integratek” consulting practice, and “Pharma Serv Academy,” a division that provides technical and regulatory standards seminars/training conducted by industry experts. The Company’s global team includes leading engineering and life science professionals, quality assurance managers and directors.

Forward Looking Statements

This news release contains “forward-looking statements” within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this news release. Although Pharma-Bio Serv’s management believes these expectations, estimates, or projections to be reasonable as of the date of this news release, forward-looking statements are inherently subject to significant business risks, economic and competitive uncertainties, or other contingencies, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. There can be no assurance that the processes being undertaken by Pharma-Bio Serv will result in growth through business development or mergers and acquisitions. Important factors that could cause Pharma-Bio Serv’s actual results or performance to differ materially from the forward-looking statements include those set forth in the “Risk Factors” section of Pharma-Bio Serv’s Annual Report on Form 10-K for the year ended October 31, 2015, and in its other filings with the Securities and Exchange Commission, which filings are available on www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.

Investor Relations Contact:

Scott Gordon
President
CorProminence LLC
scottg@corprominence.com
516 222 2560

SOURCE: Pharma-Bio Serv, Inc.

ReleaseID: 436188

NEW YORK, NY / ACCESSWIRE / January 29, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage on QuikFlo Health, Inc. (TSXV: QF) with a Price Target of CAD$1.25.

The report is available here: QF Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

QuikFlo Health is based in Calgary, Canada and was co-founded by members of the thought-leading Calgary Stroke Program with the mission of developing artificial intelligence software to read CT scans and help doctors make better treatment decisions. QuikFlo’s flagship diagnostic tool, F.A.S.T. (Fast Accurate Stroke Triage), uses an algorithm modeled from the analysis of many thousands of CT scans to calculate the volume of brain affected by an active stroke, and the volume that is likely to die without treatment. QuikFlo plans to complete a working prototype of FAST during 2016E, and expects to be on the market in 2017.

“In our opinion, QuikFlo has assembled a world-class team to execute the remaining R&D, and to commercialize FAST successfully. QuikFlo’s potential to produce meaningful improvements in patient outcome give it a substantial chance to become a standard aspect of stroke triage workflows, and therefore a highly successful healthcare IT company,” stated Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a 12-month price target of CAD$1.25 per share.”

Additional highlights from the report are as follows:

Large addressable market for stroke management products

Stroke is the leading cause of morbidity in the developed world, and one of the leading causes of mortality worlwide. The market for stroke management products, which is composed of diagnostic and therapeutic systems is expected to grow at a compound annual growth rate at 5.1%, as the prevelance of stroke doubles over the next 30 years.

The Problem with Stroke

The small- and mid-sized hospitals that comprise the vast majority of care centers worldwide lack internal expertise in stroke – on-staff stroke neurologists, neuroradiologists, and neuro-inverventionists – and routinely require help from outside experts to identify a stroke patients’ subtype and what treatment they should receive. The time that typically elapses between a patient’s CT scan, the reading of that scan, and the initiation of therapy is among the largest problems in stroke treatment, and accounts for much of the devastation of the disease. Reductions in this time interval are proven to significantly improve patient outcome.

Innovative F.A.S.T. technology

QuikFlo is developing a novel software, called FAST, that reads the CT scans of stroke patients to help first responders better understand that patient’s stroke subtype and initiate the appropriate treatment more independently. FAST uses an algorithm modeled from the analysis of many thousands of CT scans to calculate the terminal volume of brain that is currently affected by an active stroke, the volume that will die without treatment, and the amount that can be saved if the patient is referred for surgery (known as endovascular therapy, or EVT) immediately. This easy-to-digest output would enable far faster triaging of stroke patients, and a profound impact on their outcomes. It would also deliver significant cost savings to small and mid-sized hospitals, while driving increased revenue for large hospitals that can perform EVT.

Initiate coverage with a price target of $1.25

Our analysis indicates a fair value estimate of $1.25 per share implying an upside of 332.6% from the recent price of $0.29. We view QuikFlo Health as a speculative investment in the biotechnology industry with an innovative approach to develop an innovative solution for the analysis of medical images.

Please review important disclosures at www.seethruequity.com.

About QuikFlo Health, Inc.

QuikFlo Health is a Calgary-based software company that specializes in the development of innovative solutions for the analysis of medical images. QuikFlo has the exclusive rights to buy intellectual property that are being developed into an automated diagnostic tool, which interprets computerized tomography scans of stroke patients; thereby, providing specific treatment options to attending physicians. QuikFlo’s diagnostic tool has been developed at the University of Calgary and the University Stroke Center. QuikFlo’s mission is to provide cutting-edge stroke CT image analysis into a software that is fast, accurate, and easy for health professionals to use worldwide.

For more information, please visit the Company’s website at www.quikflohealth.com.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 436191

DENVER, CO / ACCESSWIRE / January 29, 2016 / Midway Gold Corp. (OTC: MDWCQ) (the “Company” or “Midway”) announces that Matt Goldfarb has joined the Board of Directors of the Company.

Mr. Bill Zisch, President and CEO, stated, “We are pleased to have Matt join the Board of Directors of Midway. His experience with restructuring companies combined with a background in the coal mining business will benefit the Midway Board. I look forward to working with Matt.”

Mr. Goldfarb is currently Chief Restructuring Officer and Acting Chief Executive Officer at Cline Mining Corporation. The Cline Mining Group is an international Canadian mining and minerals exploration company headquartered in Toronto, Canada holding coal resources in Colorado, USA and projects in Ontario, Canada and Madagascar. Most recently, Mr. Goldfarb was CEO of Xinergy Ltd., a coal company with operations in the central Appalachia area of the US. His experience includes extensive expertise in restructuring distressed loans and restructuring of companies which he gained at Pali Capital, The Blackstone Group/GSO Capital Partners, Pirate Capital LLC and Icahn Associates Corp. His public company current and former board experience includes The Pep Boys; Huntingdon Capital Corp.; Fisher Communications, Inc.; Xinergy Ltd.; Cline Mining Corporation; James River Coal Company; and CKE Restaurants, Inc.

About Midway Gold Corp.

Midway Gold Corp. is a North American exploration and mining company with precious metals properties located in Nevada and Washington states. On June 22, 2015, Midway, and certain of its subsidiaries and affiliates, including, Midway Gold US Inc., filed voluntary petitions for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Colorado. Additional information and other materials related to the restructuring, including documents filed with the Court, are available at http://dm.epiq11.com/MidwayGold.

Midway Gold Corp.
Investor Relations, 720-979-0900
www.midwaygold.com

SOURCE: Midway Gold Corp.

ReleaseID: 436192